Drug Database
DO

doxorubicin hydrochloride (Libod / Libaoduo)

✓ Approved

Shanghai Fudan-Zhangjiang · TOP2A · Small Molecule

What is doxorubicin hydrochloride?

doxorubicin hydrochloride is a small molecule developed by Shanghai Fudan-Zhangjiang. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesLibod, Libaoduo
CompanyShanghai Fudan-Zhangjiang
Drug ClassSmall Molecule
Molecular TargetTOP2A
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Shanghai Fudan-Zhangjiang

Mechanism of Action

Molecular Targets

doxorubicin hydrochloride acts on 1 molecular target:

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

doxorubicin hydrochloride is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

Related Research Articles

PubMedBiomaterials research2026-07-25

Tryptanthrin Nanoliposomal Lotion as a Corticosteroid-Free Strategy for Safe and Effective Treatment of Atopic Dermatitis.

Song Yo Han YH, Na Young-Guk YG, Yoon Moon Sup MS, Kim Da-Eun DE et al.

Atopic dermatitis is a chronic inflammatory skin disease characterized by dry skin, itching, and recurrent eczematous lesions. Although current therapeutic strategies are effective, their use is often limited due to adverse effects. Therefore, the development of safer and more effective alternatives is required. Tryptanthrin is a yellow-gold alkaloid compound with anti-atopic and various pharmacological activities. However, its poor aqueous solubility results in low topical bioavailability. A tryptanthrin-loaded liposomal lotion was developed using a design of experiments approach to improve topical delivery. The optimized formulation showed enhanced physicochemical stability and moisturizing properties, as well as improved drug release compared to free tryptanthrin. In human keratinocyte cells, the liposomal lotion exhibited lower cytotoxicity than the free tryptanthrin and demonstrated higher skin residual. In the DNCB-induced atopic dermatitis mouse model, the tryptanthrin-loaded liposomal lotion produced therapeutic effects comparable to or greater than those of 1.0% hydrocortisone, without inducing adverse effects such as skin atrophy. Overall, the tryptanthrin-loaded liposomal lotion is presented as a promising and safe strategy for the topical treatment of atopic dermatitis.

PMID 42499629
Read full article →
PubMedWater research2026-07-25

Hydrological inundation threshold regulates the carbon source-sink transition in unvegetated tidal flats.

Wu Hui H, Chen Yasong Y, Chen Shiyao S, Li Mengru M et al.

Unvegetated tidal flats cover extensive areas of global coastlines, but their role in atmospheric CO2 exchange remains poorly understood. Here we investigate how hydrological regimes regulate carbon uptake in these ecosystems through a marsh organ experiment in the subtropical Zhangjiang Estuary, China that integrated sediment-atmosphere CO2 and CH4 flux measurements, porewater geochemistry, and metagenomic sequencing. We identified a site-specific hydrological transition in which sediment-atmosphere CO2 exchange shifted from a weak source to sustained net uptake under more frequent inundation, with the transition occurring around an annual inundation frequency of approximately 10-30% in this experimental system. This transition coincided with declining porewater NO3-/Cl- and SO42-/Cl- ratios and increasing pH, dissolved CO2 concentration, and carbonate system derived estimated alkalinity, consistent with enhanced anaerobic redox processes and alkalinity-associated CO2 dissolution and retention. Although CH4 emissions increased under frequent inundation, incorporating CH4 into global warming potential did not substantially offset the CO2 sink transition. Metagenomic analyses further showed an enrichment of rTCA-related carbon-fixation taxa under frequent inundation, indicating greater microbial autotrophic carbon-fixation potential. This functional potential was associated with porewater geochemical changes and increased microbial biomass carbon, supporting the possibility of hydrologically modulated geochemical-microbial coupling during the CO2 source-sink transition. Together, our results unveil a previously unrecognized mechanism in which a hydrologically-modulated geochemical-microbial coupling drives CO2 uptake in frequently inundated sediments. These findings extend current blue carbon frameworks by highlighting the previously overlooked role of unvegetated tidal flats in coastal carbon cycling and climate regulation.

PMID 42497560
Read full article →
PubMedInternational journal of pharmaceutics2026-07-25

Repurposing glibenclamide for retinal protection: TUDCA-modified liposomes for ocular delivery.

Lana Sofia Dalla SD, Bertocchi Francesco F, Ricci Caterina C, Sissa Cristina C et al.

Glibenclamide, widely used as an oral treatment for type 2 diabetes, represents a promising example of drug repurposing. This second-generation sulfonylurea has demonstrated neuroprotective effects on ocular tissues following oral administration, showing potential benefits in the prevention and management of diabetic retinopathy and age-related macular degeneration (AMD). These findings suggest that local administration could be particularly advantageous for patients not receiving systemic glibenclamide therapy. However, to enhance ocular bioavailability and achieve sustained drug release, an appropriate delivery system is required. This study aimed to develop a topical liposomal formulation for the ocular delivery of glibenclamide. To improve penetration across biological barriers, liposome properties were optimized by incorporating tauroursodeoxycholic acid (TUDCA), a bile salt derivative that also demonstrated neuroprotective activity. The inclusion of this molecule within the lipid bilayer impacted phospholipid organization, increasing vesicle deformability, as confirmed by small-angle X-ray scattering (SAXS) analysis. Glibenclamide loading did not affect vesicle deformability and was higher in TUDCA-modified liposomes compared to conventional liposomes. Ex vivo permeation studies using isolated porcine ocular tissues (cornea, conjunctiva, and sclera) further supported TUDCA's role as an edge activator, enhancing drug penetration. Notably, glibenclamide liposomes were also able to accumulate in the sclera, forming a reservoir for sustained release over time. Finally, the liposomal formulation demonstrated good tolerability in ARPE-19 cell lines, highlighting its potential as a safe and effective system for ocular delivery of glibenclamide.

PMID 42497935
Read full article →
PubMedBritish journal of pharmacology2026-07-25

sGC stimulator BAY 41-8543 improves survival and ventricular function in a rat model of doxorubicin-induced cardiomyopathy with nephrotic syndrome.

Gawrys Olga O, Škaroupková Petra P, Kikerlová Soňa S, Vaňourková Zdeňka Z et al.

Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline-induced cardiomyopathy. This raises the hypothesis that increasing cGMP by sGC stimulation could preserve cardiac function even after HF has developed. This study aimed to evaluate the long-term effects of treatment with sGC stimulator BAY 41-8543 in a model of DOXO-induced HF with nephrotic syndrome in hypertensive rats. Male Ren-2 transgenic rats received five weekly intravenous injections of DOXO (cumulative dose 10 mg·kg-1) to induce cardiomyopathy. After two additional weeks, animals were treated with either BAY 41-8543 (10 mg·kg-1·day-1) or an ACE inhibitor (ACEi; trandolapril, 0.25 mg·kg-1·day-1). Echocardiography, blood and urine collection were performed at baseline (week -1) and 4 weeks after the treatment started to assess cardiac ventricular function, cardiac and renal biomarkers; survival at 20 weeks. Treatment with BAY 41-8543 improved long-term survival, preserved left and right ventricular systolic function and reduced myocardial expression of inflammation-related genes, particularly those linked to type I interferon signalling. ACEi provided stronger benefits in survival and structural remodelling. Kidney damage and function was not improved by any treatment compared to placebo. The sGC stimulator BAY 41-8543 exerted significant cardioprotective effects in DOXO-induced HF. Therefore, sGC stimulators may represent a promising therapeutic option for anthracycline-induced cardiomyopathy, although additional studies are required to fully investigate their therapeutic potential.

PMID 42498692
Read full article →
PubMedJournal of controlled release : official journal of the Controlled Release Society2026-07-25

Tumor-targeted CD40 ligand-functionalized extracellular vesicle mimetics enable chemoimmunotherapy for neuroblastoma.

Wang Jinkui J, Luo Junyi J, Li Jiahui J, Zhang Zhaoxia Z et al.

Neuroblastoma remains one of the most lethal pediatric solid tumors, and durable control of high-risk disease is hindered not only by inefficient tumor-selective drug delivery but also by a profoundly immunosuppressive tumor microenvironment. To address these dual barriers, we developed a chemoimmunotherapeutic vesicle-mimetic platform, DAS/CD40L-EM@DOX, by engineering CD40L-overexpressing HEK-293 T donor cells, generating extracellular vesicle mimetics through extrusion, decorating the membrane with a neuroblastoma-targeting DAS peptide, and post-loading doxorubicin. The resulting formulation preserved a nanoscale vesicular morphology, displayed CD40L on the membrane, and showed favorable particle size and zeta potential characteristics. In neuroblastoma cells, DAS decoration enhanced uptake in an α7 nicotinic acetylcholine receptor-associated manner and increased the cytotoxic and immunogenic effects of doxorubicin, as evidenced by augmented apoptosis, calreticulin exposure, and HMGB1 release. In macrophage assays, CD40L-containing vesicles shifted M2-like cells toward an M1-like phenotype, increasing CD86, TNF-α and IL-6 while decreasing CD206, IL-10 and TGF-β. Functionally, this repolarization enhanced tumor-cell phagocytosis and promoted CD8+ T-cell effector responses, including increased granzyme B, IFN-γ and IL-2 production. In tumor-bearing mice, DAS modification improved tumor accumulation and reduced off-target sequestration relative to unmodified vesicles. Therapeutically, DAS/CD40L-EM@DOX exerted the strongest inhibition of tumor growth, reduced tumor burden, prolonged survival, increased intratumoural M1-like macrophages and CD8+ T cells, decreased M2-like macrophages and regulatory T cells, and enhanced immunogenic cell-death markers in situ. Together, these findings support DAS/CD40L-EM@DOX as a dual-function vesicle-mimetic nanomedicine that couples neuroblastoma-targeted chemotherapy with macrophage reprogramming to remodel the tumor immune microenvironment and improve antitumour efficacy.

PMID 42498231
Read full article →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-07-25

Association of a failed noninvasive prenatal screening with the risk of cytogenetic abnormalities in a general-risk population: A retrospective cohort study.

An Ping P, Zhu Jie J, Zhao Ying Y, Zhou Jizi J et al.

To investigate whether noninvasive prenatal screening (NIPS) failure in a general-risk population is associated with an increased likelihood of cytogenetic abnormalities. This was a retrospective observational cohort study at a tertiary center, based on a general-risk population. Singleton pregnancies that underwent NIPS between May 12, 2017, and July 30, 2021, at the Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China, were included. The outcomes were the incidence of common autosomal aneuploidies (trisomy 21, 18, or 13), sex chromosome aneuploidies (SCAs), and copy number variations (CNVs) on the first attempt. From the reports of NIPS, the pregnancies with a failure were compared with those with a success. Propensity score overlap weighting was applied to adjust for maternal age, paternal age, parity, body mass index, method of conception and gestational age at the first blood collection. Of the 42 121 pregnancies included, 41 776 (99.18%) received reports and 345 (0.82%) did not on the first attempt at NIPS. Pregnancies with NIPS failure showed no significantly statistical difference in the risk for trisomy 21, 18, or 13 (0.29% vs. 0.23%; overlap weighting risk ratio [OW RR] 1.17; 95% CI 0.16-8.46), SCAs (4.08% vs. 7.89%; OW RR 0.53; 95% CI, 0.13-2.26) and CNVs (6.12% vs. 8.13%; OW RR 0.76; 95% CI, 0.23-2.53), compared with those with successful NIPS. These findings remained consistent in the sensitivity analyses. The evidence was insufficient that NIPS failure after first-trimester ultrasound screening could be associated with an increased risk of common autosomal aneuploidies, SCAs, and CNVs. Our findings suggest that in a general-risk population those who experience NIPS failure need to be managed on the basis of their basic risk.

PMID 42498494
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about doxorubicin hydrochloride